Article
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study
All News
Article
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Dr. John Cush
Tweet
Older Lupus Patients Need Follow-Up After Hospital Discharge
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
https://t.co/4mFctXGQH9 https://t.co/2Q1z03myud
Dr. John Cush
Tweet
It's time to play, know your numbers! You know that famous game we play almost every other week, every other year.
https://t.co/JgCJzSuzHZ https://t.co/oiyB8vCOuD
Dr. John Cush
Tweet
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf
Dr. John Cush
Tweet
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?
Dr. John Cush
Tweet
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p
Dr. John Cush
Tweet
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ
Dr. John Cush
Tweet
2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD
Dr. John Cush
Tweet
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/Xn9Ur199nv
Dr. John Cush
Tweet
Dr Eric Ruderman #RWCS23
Bee Venom around since 1859, vaguely better than placebo https://t.co/3Xl7SZwQPm
Dr. Rachel Tate
Tweet
ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilars” @RheumNow @RWCSmtg #RWCS23
Dr. Rachel Tate
Tweet
Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg
Dr. Rachel Tate
Tweet
Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https://t.co/KstyKdjWn2
Dr. Rachel Tate
Tweet
2022 EULAR recs for RA treatment @RheumNow @RWCSmtg #RWCS23 https://t.co/nWCcFJyIhz
Dr. John Cush
Tweet
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live!
Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more.
https://t.co/gAKQYxhTMY https://t.co/zMOGfhRrg2
Dr. John Cush
Tweet
Know Your Numbers! Have a chance to tune in to last week's podcast?
https://t.co/A6bYIahvBF https://t.co/ZAgZ3FvL0H
Dr. John Cush
Tweet
Lg vessel US study compared 44 LV-GCA vs 42high-risk atherosclerosis pt.Intima-media thickness (IMT) was signif. higher w/ GCA. IMT ≥ 1 mmseen in 31/44 axillary, 30/44 subclavian in GCA; but only in 2/42 axillary & 3//42 subclavian in atherosclerosis grp.https://t.co/DGMOfflcVR https://t.co/QVBbdrcd3I
Dr. John Cush
Tweet
Retrospective study of 64 gout pts having orthopedic surgery - perioperative flares more likely with Incr SUA, DM, tophi and diuretics. In 12 mos following surgery, recurrent gout more if ^SUA (45% vs 11%) & those w/ topic ((RR = 4.8; P = 0.029) https://t.co/iMDSWnb5Dv https://t.co/ZwUKBkZbSL
Dr. John Cush
Tweet
NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH
